PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
36.29%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.62%. Joel Greenblatt would investigate if growth quality matches quantity.
0.32%
Cost growth of 0.32% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify cost control.
57.21%
Gross profit growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.80%. Joel Greenblatt would investigate competitive advantages.
-43.53%
Margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
-13.16%
R&D reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
-3.55%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
41.98%
Marketing expense change of 41.98% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
-38.63%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
10.53%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.09%. Jim Chanos would check for waste.
99.84%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.28%. Jim Chanos would check for waste.
-3.41%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
19.37%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.17%. Jim Chanos would check for overinvestment.
203.35%
EBITDA growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.22%. Joel Greenblatt would investigate advantages.
114.13%
Margin change of 114.13% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-181.24%
Operating income decline while Drug Manufacturers - Specialty & Generic median is 0.48%. Seth Klarman would investigate causes.
-159.61%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-63.57%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is -6.82%. Seth Klarman would investigate advantages.
-64.79%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-74.17%
Pre-tax margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-92.27%
Tax expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-57.90%
Net income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-69.11%
Net margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-53.60%
EPS decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-60.74%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
0.09%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would check for issues.
0.10%
Diluted share change of 0.10% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.